Kornimate/medical-research-clean huggingface dataset:
urinary heparanase activity as a predictor of acute kidney injury in critically ill adults

Conditions: Sepsis; Trauma; Shock; Acute Kidney Injury

Summary: across the world, the most common cause of dying in the icu is a disease called "sepsis". sepsis is a disease in which the body's protective response to infection becomes too intense, unnecessarily damaging important organs in the body. kidney damage during sepsis is particularly bad, as a person's chance of survival drops significantly when he or she develops kidney failure. this study plans to learn more about how to detect (and thus prevent) kidney failure early in sepsis. the current tests doctors use only detect kidney failure once it's already happened. we must therefore find better ways of detecting kidney failure earlier, when there is still a chance to protect the kidneys. in this study, patients will provide a one-time sample of urine. we will check this urine for signs of a protein called "heparanase", which we believe is important in early kidney failure. we will then see if high heparanase activity in urine predicts the risk of developing kidney failure. we will compare results from patients with sepsis with results from patients with trauma, allowing us to determine if heparanase is only important in sepsis kidney failure.


Eligibility criteria:
inclusion criteria: 1. septic shock or major trauma. septic shock will be defined by standard criteria including (a) the presence of the systemic inflammatory response syndrome (sirs), (b) evidence of infection, and (c) treatment with vasopressor medications for \> 4 hours despite \> 30 ml/kg intravenous crystalloid resuscitation. as a critically-ill comparator group, we will also enroll adult patients admitted (within 24 hours prior to screening) to the denver health surgical icu with major trauma, as defined by an injury severity score of \> 15. exclusion criteria: exclusion criteria include anuria, prisoners, absence of a routinely-inserted urine collection device, or gross hematuria. additionally, patients with known genitourinary malignancy will be excluded, given that cancers are known to overexpress heparanase. additional exclusion criteria include age \< 18 years, and pregnant women.

Keywords: sepsis trauma shock acute kidney injury heparanase
cystoid macular edema after vitrectomy for rhegmatogenous retinal detachment

Conditions: Cystoid Macular Edema

Summary: to investigate the incidence of cystoid macular edema in eyes with primary rhegmatogenous retinal detachment successfully treated with vitrectomy with gas tamponade, and to evaluate the clinical variables associated with its development.

this is an observational, retrospective, multicentre study. the study is based on the retrospective collection of clinical data from patients undergoing gas tamponade vitrectomy for rhegmatogenous retinal detachment. the collection of such data by the investigators will take place at each participating center anonymously. demographics, systemic, and preoperative, intraoperative and post-operative data will be collected the sample size was calculated to obtain approximately 200 patients with cystoid macular edema. since cystoid macular edema has been detected in 13% of patients after retinal detachment gas vitrectomy, and assuming that this event can occur between 10% and 15% of cases, the study will include at least 2000 cases.

Eligibility criteria:
inclusion criteria: * primary rhegmatogenous retinal detachment treated with vitrectomy with gas tamponade; * follow-up of 3 months or more; * age \> 18 years ; * no previous eye surgery, except cataract surgery performed at least 6 months after hospitalization for retinal detachment; * anatomical success, i.e. retinal re-attachment, after a single gas vitrectomy; * no other eye surgery during follow-up; * availability of optical coherence tomography (oct) imaging exclusion criteria: * history of other eye diseases (glaucoma, age-related macular degeneration, uveitis, diabetic retinopathy, maculopathy); * macular hole; * recurrent retinal detachment; * use of silicone oil is used as a tamponading agent

Keywords: cystoid macular edema rhegmatogenous retinal detachment vitrectomy gas tamponade
registry to investigate the efficacy and safety of venablock vein sealing system for varicose veins in singapore

Conditions: Varicose Veins; Venous Reflux; Chronic Venous Insufficiency

Summary: to assess the efficacy of the venablock©vein sealing system (vbvs) for the treatment of lower extremity superficial truncal veins in a real-world clinical setting in a multi-racial asian population in singapore.

the purpose of the registry to investigate the efficacy and safety of venablock©vein sealing system for varicose veins in singapore (riveria), is to investigate the performance of cyanoacrylate glue closure (cac) using this device, in which multiple incompetent superficial saphenous truncal veins (great saphenous (gsv), short saphenous vein (ssv), anterior accessory saphenous vein (aasv) will be treated at the same setting, and compression stockings will not be used post-operatively. the inclusion criteria for this study will be liberalized, and veins up to 12mm in diameter will be treated. as such,riviera will be the first prospective trial conducted in asia on a predominantly asian cohort of patients to report on the performance of venablock© for blocking incompetent truncal veins. this study specifically focuses on the initial technical outcomes, safety, anatomical occlusion, and patient experience after treatment with venablock© with broader inclusion of patients than previous caucasian based trials.

Eligibility criteria:
inclusion criteria: 1. age \> 21 years old and ability to understand the requirements of the study and to provide informed consent 2. c2-c6 varicose veins/cvi (ceap class 1 patients will be excluded) 3. symptomatic primary gsv,ssv or aasv incompetence, with reflux \> 0.5 seconds on colour duplex, including one or more of the following symptoms: aching, throbbing, heaviness, fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort, swelling 4. patients who had gsv, ssv or aasv diameters of 3mm to 12mm in the standing position exclusion criteria: 1. current dvt or history of dvt 2. pregnant patients 3. arterial disease (abpi\<0.8) 4. sepsis 5. patient who are unwilling to participate 6. inability or unwillingness to complete the time-point questionnaires 7. adverse reaction to sclerosant or cyanoacrylate previously 8. multiple drug allergies 9. previous intervention with the venaseal cyanoacrylate glue closure system 10. severely tortuous gsv, ssv or aasv 11. life expectancy \< 1 year 12. active treatment for malignancy other than non-melanoma skin cancer 13. current, regular use of systemic anticoagulation (e.g., warfarin, heparin) 14. daily use of narcotic analgesia or nsaids to control pain associated with venous disease

Keywords: endovenous ablation
prediction of mmse scores for cognitive impairment

Conditions: Cognitive Impairment; Healthy Control

Summary: this study aims to explore the potential of using machine learning (ml) algorithms to predict cognitive status, specifically mmse scores, based on oral health and demographic data. the objective is to evaluate the effectiveness of various ml models and identify the most relevant oral health indicators for predicting mmse scores of 30 (normal cognition) or ≤26 (cognitive impairment) in individuals aged 60 and above.

this cross-sectional study utilizes oral health and demographic data from two existing cohort studies: the european collaborative study support monitoring and reminder technology for mild dementia (smart4md) and the swedish national study on aging and care (snac-b). participants aged 60 years or older will be included in the analysis. the data will be used to develop and evaluate machine learning models for predicting cognitive status. objectives: 1. primary objective: to assess the potential of oral health parameters for binary classification of mmse scores (30 vs. ≤26). 2. secondary objective: to identify the most influential oral health parameters contributing to cognitive impairment predictions. 3. tertiary objective: to compare the performance of random forest (rf), support vector machine (svm), and catboost (cb) classifiers in predicting mmse scores using oral health data.

Eligibility criteria:
inclusion criteria: * individuals aged 60 years or older. * participants with recorded oral health parameters and mmse scores of either 30 or ≤26. exclusion criteria: * individuals with mmse scores of 27, 28, or 29, as these scores represent a transition phase between normal cognition and cognitive impairment, which could introduce variability. * individuals younger than 60 years.

Keywords: classification machine learning mini-mental state examination cognitive impairment oral health
hemiepiphysiodesis by eight plate versus osteotomy in the management of pediatric coronal knee deformities

Conditions: Genu Varum

Summary: coronal angular deformities of lower limb in children are a common finding in pediatric orthopedic surgery.these angular deformities can be idiopathic in origin, or they can emerge secondary to congenital and acquired abnormalities. persistent coronal plane deformities around knee (genu varum/valgum) could lead to meniscal tears, collateral ligament laxity, cartilage degeneration, and early osteoarthritis due to gradual mechanical axis disruption

eight-plates first described by stevens are simple to use .moreover, owing to the flexible screw/plate connection, fewer complications in terms of implant loosening and fracture can be expected.good results aswell as low reboundand complication rates have been recorded for the first series of cases

Eligibility criteria:
inclusion criteria: * growth plate still open at time of surgery exclusion criteria: * epiphyseal plate involved in trauma resulting in a bridging callus formation,
cervical cancer detection using optical spectroscopy

Conditions: Cervical Cancer

Summary: the objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.


Eligibility criteria:
inclusion criteria: * undergoing colposcopy for the diagnosis of cervical cancer * leep for the treatment of cervical cancer in early stages. * follow-up pap smear in surveillance exclusion criteria: * women under the age of 18 (minors) will be excluded from this study. * patients will be excluded if she has had a recent episode of bleeding or preterm labor. * subjects who are not competent to give consent will excluded

Keywords: cervical cancer leep colposcopy pap smear
immunogenicity of hepatitis b vaccination among drug users

Conditions: Hepatitis B Vaccination

Summary: uptake, adherence, and completion of vaccination among drug users were low, and their immune function and immune response to hepatitis b vaccination were also suboptimal, indicating that the current practice of hepatitis b vaccination can't protect drug users from hbv infection. this is a randomized, open-label, blank-controlled trial, conducted among drug users with drug rehabilitation. this study will compare the immunogenicity and safety of three intramuscular 20µg and 60µg recombinant hepatitis b vaccines at months 0, 1, and 6 among drug users

comparison of 2 vaccination strategy against hepatitis b in drug users intervention: arm 1 : receive three intramuscular injections of 60 µg recombinant hepatitis b vaccine at months 0, 1 and 6; arm 2 : receive three intramuscular injections of 20 µg recombinant hepatitis b vaccine at months 0, 1 and 6; arm 3 : receive no vaccination during the study period.

Eligibility criteria:
inclusion criteria: * aged between 18 and 70 years at the enrolment * current illicit drug users before drug rehabilitation * negative for hepatitis b surface antigen (hbsag) and hepatitis b surface antibody (anti-hbs) at enrollment * having spent acute physiological detoxification phase exclusion criteria: * any intolerance or allergy to any component of the vaccine * ongoing opportunistic infection * liver disease * hemopathy * cancer * unexplained fever in the last week before the recruiting

Keywords: hepatitis b vaccination immunogenicity randomized controlled trial drug abuse
elderly cancer patient

Conditions: Hematologic Malignancies; Solid Cancer

Summary: the management of older patients with cancer has become a major public health concern in western countries because of the aging of the population and steady increase in cancer incidence with advancing age. cancer treatment of aged patients is complex due to comorbidities, polypharmacy and functional status. the heterogeneity of the older population in terms of comorbidities and functional status may explain the difficulty in establishing management recommendations. study hypothesis is that a geriatric consultation using geriatric assessment (ga) can evaluate patient's resource and strengths, in order to help oncologist to define the most effective treatment. the ga developed by geriatricians and recommended by the international society of geriatric oncology (siog), is a multidimensional assessment of general health status; comorbidities; functional status; nutritional, cognitive, psychological, and social parameters; and medications. the ga uses validated geriatric scales to produce an inventory of problems, which can then serve to develop an individualized geriatric intervention plan; it may be an important step in selecting elderly patients for cancer screening and treatment. the objectives are: * to assess the role of ga for decision making process for older patients with cancer * to identify geriatric and oncologic factors associated with overall survival, treatment feasibility, toxicities, morbidities * to develop and/or validate screening tests for frailty in geriatric oncology * to develop and validate frailty classifications method: the elcapa (elderly cancer patient) survey is a french multicentric prospective study that includes all patients age 70 years or older who has a diagnosis of solid cancer or hematologic malignancies in french hospitals


Eligibility criteria:
inclusion criteria: * patient aged 70 years or older * diagnosed cancer at all stage * referred to a geriatrician for ga * given oral non-opposition from patient or a legally mandated person exclusion criteria: * oral opposition

Keywords: elderly cancer geriatric assessment treatment epidemiology
pilot trial of external warming in septic patients

Conditions: Sepsis

Summary: the purpose of this study is to determine whether externally warming critically ill afebrile adult septic patients will improve indices of immune function and/or clinical outcomes.


Eligibility criteria:
inclusion criteria: * admitted to a surgical or medical intensive care unit * age greater than 18 years * diagnosis of sepsis within 24 hours of enrollment * requirement for mechanical ventilation with expected duration of mechanical ventilation \> 48 hours * goal richmond agitation sedation scale (rass) \< 0 * maximum baseline temperature (within previous 24 hours) \< 38.3°c exclusion criteria: * treatment with chemotherapy within 6 months of enrollment * treatment with corticosteroids at a dose \> 300 mg/day hydrocortisone (or equivalent) * history of solid organ transplant on any immunosuppression medication * history of immunological disease * history of chronic infection with hepatitis b or c virus * history of acute stroke, acute coronary syndrome, or severe head injury requiring osmotic therapy within 7 days prior to enrollment * history of multiple sclerosis * contraindications to both bladder or esophageal core temperature monitors or to forced air warming blankets * moribund status * sepsis without source control
denintuzumab mafodotin (sgn-cd19a) combined with rchop or rchp versus rchop alone in diffuse large b-cell lymphoma or follicular lymphoma

Conditions: Diffuse, Large B-Cell, Lymphoma; Follicular Lymphoma, Grade 3b; Transformed Lymphoma / DLBCL

Summary: this is a phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with rchop or rchp compared with rchop alone as front-line therapy in patients with diffuse large b-cell lymphoma or follicular lymphoma grade 3b.

in part a of the study, patients will be randomized 1:1 to receive denintuzumab mafodotin plus rchop (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or denintuzumab mafodotin plus rchp (rituximab, cyclophosphamide, doxorubicin, and prednisone) to assess the safety of these 2 combination regimens. part b of the study is designed to evaluate the antitumor activity and safety of denintuzumab mafodotin in combination with either rchop or rchp (experimental arm) compared with rchop alone (comparator arm).

Eligibility criteria:
inclusion criteria: * treatment-naive patients with histologically confirmed systemic de novo or transformed diffuse large b-cell lymphoma (dlbcl) (from follicular or marginal zone lymphoma), or follicular lymphoma (fl) grade 3b; * patients must have high intermediate or high risk disease * tumor tissue available from most recent biopsy to determine cell of origin * fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease greater than 1.5cm diameter * eastern cooperative oncology group performance status ≤2 * age 18 years or older * adequate study baseline laboratory parameters exclusion criteria: * previous history of treated indolent lymphoma * history of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years * history of progressive multifocal leukoencephalopathy * cerebral/meningeal disease related to the underlying malignancy * patients with the following ocular conditions: corneal disorders, monocular vision (ie. best corrected visual acuity greater than or equal to 20/200 in one eye), or active ocular disorders requiring treatment

Keywords: antibodies, monoclonal sgn-19a denintuzumab mafodotin dlbcl antibody-drug conjugate antigens, cd19 hematologic diseases immune system diseases immunoproliferative disorders immunotherapy lymphatic diseases lymphoma lymphoma, b-cell lymphoma, large b-cell, diffuse lymphoma, non-hodgkin monomethyl auristatin f neoplasms neoplasms by histologic type transformed lymphoma / dlbcl cyclophosphamide doxorubicin liposomal doxorubicin prednisone rituximab vincristine alkylating agents anti-inflammatory agents antibiotic, antineoplastic antimitotic agents antineoplastic agents, alkylating antineoplastic agents phytogenic antirheumatic agents glucocorticoids drug therapy follicular lymphoma grade 3b immunosuppressive agents
study evaluating b-domain deleted recombinant factor viii (bddrfviii, refacto af) in patients with hemophilia a undergoing elective major surgery

Conditions: Hemophilia A

Summary: this study will examine the efficacy and safety of refacto af in patients with severe and moderately severe hemophilia a undergoing elective major surgery when administered by either bolus injections (bi) or continuous infusion (ci).


Eligibility criteria:
* male, at least 12 years old, with severe hemophilia a undergoing major elective major surgery requiring fviii replacement for at least 6 days. negative fviii inhibitor test at screening and no past history of inhibitor. * previously treated with at least 150 exposure days to any factor viii product * normal hepatic and renal function tests and no other bleeding disorder

Keywords: hemophilia a bleeding disorder
risk stratification in acute care: the meaning of supar measurement in triage

Conditions: Triage; Risk Stratification With Biomarker

Summary: will clinical outcome for patients be improved if triage in acute wards and emergency rooms is supplemented with a prognostic biomarker?

in a health care system where the general population is growing, more patients are living with chronic conditions and the hospitals are reducing beds and length of stay, it is crucial to perform safe and fast risk stratification of patients presenting in the emergency departments. risk stratification is currently performed with a combination of measurement of the vital signs and assessment of the primary complaint. the aim of the current study is to assess whether the supplement of biomarkers can improve the risk stratification in regard to mortality, readmissions and improve overall patient flow in the emergency departments. soluble urokinase plasminogen activating receptor (supar) is the soluble form of urokinase-type plasminogen activator receptor (upar). upar is present on various immunological active cells, as well as endothelia and smooth muscle cells. it is believed that supar mirrors the inflammatory response in patients. previous studies have shown a strong association with mortality and severity of disease in a broad variety of conditions (infection, hepatic-, renal-, cardiac- and lung disease) as well as a possible marker of disease development in the general population. these abilities indicate that supar although unspecific would be ideal to identify patients at high- and at low-risk. the aim is to target interventions and limited clinical focus where it is most beneficial. in unselected patients supar is one of the strongest prognostic biomarker available to date. it is not known whether information on prognosis in the emergency department can be used to prevent death, serious complications or reduce admissions and readmissions. the purpose of the current study is to examine if introduction of the biomarker supar and education of doctors in the meaning of supar levels and association to disease, can reduce mortality, admissions and readmission in patients referred to the emergency rooms.

Eligibility criteria:
inclusion criteria: * patients presenting acutely to the acute ward/emergency department and have blood samples done which include both hemoglobin, c reactive protein and creatinine within 6 hours of registration within the study period. the study is carried out in 2 hospitals in the capital of denmark. exclusion criteria: * patients presenting in pediatric, gynecological or obstetric units. patients not being examined with blood samples.

Keywords: triage risk stratification acute care supar
association of c-reactive protein-albumin-lymphocyte index (cally) with all-cause mortality in diabetic patients

Conditions: Diabetes

Summary: based on retrospective cohort data from 3,988 diabetic patients in the nhanes database, this study is the first to show a significant negative correlation between the cally index and all-cause mortality in diabetic patients, with good predictive ability for their survival risk. our findings can help clinicians better assess disease progression in diabetic patients and provide a reference for personalized, precision medicine.

all analyses accounted for nhanes sample weights, clustering, and stratification. we used empowerstats (v4.1, www.empowerstats.com) and r software (v4.4.1, www.r-project.org). continuous variables were expressed as weighted mean ± standard error (se), and categorical variables as weighted percentages. associations between the cally index and all-cause mortality were assessed using cox proportional hazards models. model 1 was the unadjusted crude model. model 2 included adjustments for age, sex, race, bmi, pir, education, smoking, and alcohol consumption. model 3 was the fully adjusted model including additional covariates, hdl, tc, bun, uric acid, scr, physical activity, energy intake, hypertension, cvd. kaplan-meier survival curves were used to compare survival across cally quartiles; differences were assessed using log-rank tests. nonlinear associations were examined with smoothed curve fitting. subgroup analyses explored consistency across strata. roc curves and auc were used to compare the predictive performance of cally, sii, plr, and nlr. p \< 0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: (1) self-reported doctor-diagnosed diabetes; (2) fasting blood glucose ≥ 7.0 mmol/l; (3) two-hour oral glucose tolerance test blood glucose ≥ 11.1 mmol/l; (4) glycated hemoglobin a1c (hba1c) ≥ 6.5%; or (5) use of hypoglycemic medication.

Keywords: diabetes